Dragon Pharma, Europe
Proviron
Oral · 25 mg/tab · 100 tabs
$94.00
Compound ID
Mesterolone
Dosage
25–200 mg/day
Concentration
20 mg/tablet
Form
100 Tablets × 20 mg
Half-life
8–12 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Mesterolone 25mg — Pharmaceutical-Grade DHT Derivative for Estrogen Modulation, Libido Enhancement & Cycle Optimization
Dragon Pharma Mesterolone 25mg represents a unique and indispensable tool within the advanced performance enhancement landscape—a compound that occupies a distinct pharmacological niche as a pure androgenic agent devoid of direct anabolic activity yet possessing profound utility for physique refinement, hormonal optimization, and cycle ancillary support.
Originally developed by Schering in the late 1960s under the legendary Proviron brand, this 1-alpha-methylated dihydrotestosterone derivative has transcended decades of evolving supplementation science to remain a cornerstone of sophisticated stacking protocols. Unlike conventional anabolic steroids that drive muscle protein synthesis, Mesterolone exerts its influence through sex hormone-binding globulin displacement, aromatase inhibition, and potent androgenic signaling in target tissues.
Dragon Pharma's precisely manufactured 25mg tablets deliver this time-tested compound with modern pharmaceutical precision, providing athletes with a versatile, liver-safe agent for enhancing free testosterone availability, preserving libido, combating estrogenic side effects, and maintaining muscle hardness across bulking, cutting, and post-cycle transitions.
What is Dragon Pharma Mesterolone?
Mesterolone is a synthetic androgen and anabolic steroid chemically classified as a 1-alpha-methylated derivative of dihydrotestosterone (DHT). This structural lineage confers exceptionally strong androgenic properties while simultaneously preventing aromatization via the aromatase enzyme—meaning the compound cannot convert to estrogen under any circumstances. Unlike nearly all other oral anabolic agents, Mesterolone is not C17-alpha alkylated, eliminating the hepatotoxic burden that restricts cycle length for most oral steroids.
However, this same absence of C17-aa modification renders the compound rapidly reduced to inactive metabolites within muscle tissue, explaining its lack of direct anabolic effect on skeletal hypertrophy. Its pharmacological value instead lies in peripheral mechanisms: extremely high binding affinity for sex hormone-binding globulin (SHBG), weak competitive inhibition of aromatase, and potent androgen receptor activation in tissues where DHT itself serves as the primary androgenic mediator.
Dragon Pharma's 25mg oral tablets provide a convenient, accurately dosed delivery system for this uniquely positioned ancillary compound.
Key Benefits / Effects
- Estrogen Modulation & Aromatase Inhibition: Mesterolone weakly inhibits the aromatase enzyme while simultaneously occupying androgen receptors in breast tissue, creating a dual-action anti-estrogenic environment that helps prevent gynecomastia and water retention when stacked with aromatizing compounds.
- Free Testosterone Amplification: The compound exhibits one of the highest binding affinities for SHBG of any steroid, displacing bound testosterone and increasing the biologically active free testosterone fraction without increasing total dosage.
- Libido & Sexual Function Restoration: Potent androgenic signaling in the central nervous system and genital tissue frequently restores diminished libido, erectile quality, and sexual desire that can be suppressed during intensive anabolic cycles or post-cycle recovery phases.
- Muscle Hardness & Density: Pure androgenic activity in the absence of estrogenic fluid retention produces a dry, tight, and defined aesthetic, enhancing muscular detail and vascular visibility particularly valued during cutting or pre-contest phases.
- PCT Bridge & HPTA Support: During the transition off suppressive compounds, Mesterolone provides exogenous androgenic support that mitigates low-testosterone symptoms while the hypothalamic-pituitary-gonadal axis gradually recovers endogenous function.
- Spermatogenesis & Fertility Support: The compound has been clinically utilized to improve sperm count and motility in androgen-deficient men, offering potential reproductive health benefits during or after intensive hormonal protocols.
How Dragon Pharma Mesterolone Works
Mesterolone initiates its effects through several distinct peripheral mechanisms rather than direct genomic anabolism in muscle tissue. First, its extraordinarily high affinity for sex hormone-binding globulin allows it to displace endogenous testosterone from carrier proteins, dramatically increasing the free testosterone concentration available to activate androgen receptors in muscle, bone, and central nervous tissue. Second, the compound exhibits weak competitive inhibition of the aromatase enzyme, modestly reducing the conversion of testosterone and other aromatizing steroids into estradiol.
Third, as a non-aromatizing DHT derivative, it binds directly to androgen receptors in breast and adipose tissue, exerting an anti-estrogenic effect at the receptor level that complements its weak enzymatic inhibition. In the central nervous system, Mesterolone's potent androgenic signaling enhances dopaminergic pathways and nitric-oxide-mediated erectile function, explaining its pronounced pro-libido effects. The absence of C17-alpha alkylation means the compound undergoes rapid hepatic metabolism via standard phase I and II pathways rather than the toxic oxidative stress associated with alkylated orals, rendering it exceptionally liver-safe and suitable for extended-duration administration.
Usage Information
Dragon Pharma Mesterolone is supplied as 25mg oral tablets and is distinguished by its flexibility for both short-term cycle support and extended therapeutic-style administration. Male users typically employ 50–100mg daily, divided into two to four administrations to maintain stable plasma concentrations and consistent SHBG saturation. A standard protocol for cycle support consists of 50mg daily, while more aggressive estrogen management or libido restoration may utilize 75–100mg daily. When employed as a post-cycle bridge or HPTA recovery aid, a common approach initiates at 50–100mg daily for the first week, followed by a 25mg reduction to a maintenance dose as natural testosterone production gradually resumes.
For synergistic anti-estrogenic stacking, 50mg of Mesterolone combined with 20mg of Tamoxifen Citrate provides comprehensive estrogen receptor blockade and aromatase inhibition. Female users seeking enhanced muscle hardness and metabolic effects may utilize a single 25mg tablet daily, though vigilance for virilizing symptoms is essential. Because Mesterolone is not hepatotoxic, cycle length is not constrained by liver stress and can extend for many weeks or even months under appropriate health monitoring, though androgenic side effects and lipid profiles should guide duration decisions.
Quality & Manufacturing
Dragon Pharma upholds rigorous pharmaceutical manufacturing standards, with each Mesterolone batch subjected to comprehensive quality-control testing to verify identity, purity, and dosing accuracy. The 25mg tablets are produced under controlled conditions to ensure uniform active ingredient distribution and tablet hardness, supporting consistent dissolution and bioavailability. In a marketplace where ancillary compounds are frequently underdosed or contaminated with unrelated hormonal agents, Dragon Pharma's commitment to analytical transparency provides athletes with the confidence to integrate Mesterolone into long-term protocols.
The non-hepatotoxic nature of this compound makes dosing precision particularly important for extended cycles, as users may remain on the product for many weeks and must trust that each tablet delivers exactly the stated 25mg of pure Mesterolone without the variable potency that characterizes unverified alternatives.
Possible Side Effects / Safety Information
- Androgenic Dermatological Effects: As a potent DHT derivative, Mesterolone can increase sebaceous gland activity leading to oily skin and acne, accelerate androgenic alopecia in genetically predisposed individuals, and stimulate terminal hair growth on the face and body.
- Virilization in Women: Female users face risk of voice deepening, clitoral enlargement, hirsutism, and menstrual disruption even at conservative 25mg daily doses; immediate discontinuation is required upon symptom onset.
- Cardiovascular Lipid Impact: Prolonged administration at elevated doses may adversely affect cholesterol profiles, potentially reducing HDL cholesterol and elevating LDL cholesterol, necessitating dietary vigilance and periodic lipid monitoring.
- Absence of Hepatotoxicity: Unlike C17-alpha alkylated oral steroids, Mesterolone does not stress hepatic enzyme systems and requires no liver support supplementation, representing one of its primary safety advantages.
- Mild Suppression at High Doses: While generally considered minimally suppressive compared to anabolic steroids, very high doses or extended durations may exert some negative feedback on the hypothalamic-pituitary-gonadal axis in sensitive individuals.
- Psychological Androgenicity: Some users report increased irritability, aggression, or heightened confidence consistent with strong androgen receptor activation in central nervous tissue.
Why Choose Dragon Pharma Mesterolone?
In an industry saturated with liver-toxic orals and complex ancillary cocktails, Mesterolone stands apart as a uniquely safe, versatile, and time-proven compound—and Dragon Pharma's manufacturing precision ensures users capture its full benefits without the uncertainty of underdosed or contaminated alternatives.
The verified 25mg potency per tablet enables mathematically precise stacking calculations, whether the goal is SHBG displacement to amplify a testosterone base, estrogen management during aromatizing cycles, libido preservation through PCT, or year-round androgenic support without hepatic burden. For the informed athlete who understands that performance enhancement is as much about hormonal optimization and side-effect mitigation as it is about raw anabolic power, Dragon Pharma Mesterolone represents an essential, non-negotiable component of a sophisticated, health-conscious protocol.
Lab Report
Lab Report: 27 mg/tab
26 Mar 2026
20 mg/tab of label claim
| Analysis Date | 2026-03-25 |
| Lot / Batch ID | #DR20A |
| Measured Potency | 27 mg |
| Quality Assessment | Potency verified, purity passed, heavy metals passed. |
| Current Production Batch | Latest Batch |
Verify this result with your scratch-off code at the DPStore register.
Hey!! So, Mark…thank you for making this entire process transparent (or as transparent as one could be in this business.) It was easy, I really enjoyed the 15% off for using BTC ( which btw took care of my ENTIRE SHIPPING COSTS) and still the easiest of all crypto to obtain. And it was “marked as shipped” yesterday, but it likely went out a day BEFORE being marked shipped; which is great for me, because in such a situation, it FEELS like your package is coming faster. And as far as the quality…we’ll just have to see on that, because I’ve not tried them yet, I cannot make an assessment right this minute. But with the proviron, i should know whether WHETHER THEY'RE REAL or whether they’re not within a week. But yeah,…thanks a lot for answering my customer service tickets like usually within 3 hours. So, you have a wonderful business model here going for you, now let’s see if the product matches the customer experience—oh yeah, the user interface is very easy to maneuver. Thanks again, mark. P.S. my package is arriving tomorrow!! Record time, man…record time.
Product FAQ
Questions, answered
While pharmaceutical aromatase inhibitors block the enzymatic conversion of testosterone to estrogen, Mesterolone operates through multiple complementary pathways: weak aromatase inhibition, direct androgen receptor occupancy in estrogen-sensitive tissues, and SHBG displacement to increase free testosterone. It does not reduce estrogen as aggressively as dedicated AIs, but it simultaneously enhances androgenic tone and libido—effects that pure anti-aromatase drugs do not provide. Many advanced users combine Mesterolone with low-dose AIs for comprehensive estrogen management.
No. Due to its rapid reduction to inactive metabolites within muscle tissue, Mesterolone possesses negligible direct anabolic activity in skeletal muscle. Its value lies entirely in ancillary mechanisms: increasing free testosterone from other compounds, reducing estrogenic side effects, enhancing muscle hardness through androgenic signaling, and preserving libido. It should never be used as a standalone bulking agent but rather as a strategic adjunct to true anabolic steroids or SARMs.
Because Mesterolone is non-hepatotoxic and minimally suppressive at moderate doses, it can be employed during the transitional period between cycles to maintain androgenic tone, preserve libido, and mitigate the psychological and physical slump of low testosterone without significantly delaying hypothalamic-pituitary-gonadal axis recovery. A typical bridge protocol uses 50–100mg daily for one week, tapering to 25–50mg as natural production resumes, providing exogenous androgenic support without the deep suppression of full anabolic steroids.
Circulating testosterone binds primarily to sex hormone-binding globulin (SHBG), rendering it biologically inactive. Mesterolone exhibits an extraordinarily high affinity for SHBG—higher than testosterone itself—allowing it to competitively displace bound testosterone from carrier proteins. The displaced testosterone then becomes free or albumin-bound, dramatically increasing the fraction available to activate androgen receptors in muscle and other target tissues. This effectively amplifies the potency of any concurrent testosterone or anabolic steroid without increasing the injected or ingested dosage.
Female use requires extreme caution due to the compound's potent androgenic activity. While some female athletes utilize a single 25mg tablet daily for enhanced muscle hardness and metabolic rate, the risk of irreversible virilization—including voice deepening, clitoral enlargement, and hirsutism—is real and dose-dependent. Women who choose to use Mesterolone should limit duration to 4–6 weeks, monitor closely for early androgenic symptoms, and discontinue immediately upon any masculinizing changes. It is generally not recommended for female beginners.
At standard doses of 25–50mg daily, suppression is generally minimal to negligible compared to anabolic steroids. However, at higher doses approaching 100–150mg daily or during extended months-long protocols, some negative feedback on luteinizing hormone and follicle-stimulating hormone may occur in sensitive individuals. The suppression depth is far shallower than that produced by testosterone or its derivatives, which is why Mesterolone can function as a bridge compound. Nonetheless, users should not assume complete immunity from endocrine disruption at extreme doses.
Both compounds are DHT derivatives prized for dry, hard aesthetics, but they operate through different mechanisms and potency levels. Masteron (Drostanolone) possesses direct anabolic and anti-estrogenic activity with more pronounced effects on muscle density and conditioning at moderate doses. Mesterolone lacks direct anabolic action but offers superior convenience as an oral agent, stronger SHBG displacement, and significantly better safety margins due to non-hepatotoxicity. Masteron is typically preferred for pre-contest hardening, while Mesterolone excels as a versatile, long-term cycle support and libido-preservation agent.
Because Mesterolone is not C17-alpha alkylated and does not stress the liver, it is among the few oral androgenic compounds that can theoretically be used for extended durations without hepatic concerns. However, year-round use is not without risks: prolonged androgen exposure may impact lipid profiles, accelerate hair loss in predisposed individuals, and potentially exert mild suppression at high doses. Many experienced users cycle Mesterolone in 8–12 week blocks with brief intervals, while others incorporate it continuously at conservative 25–50mg doses with quarterly blood work monitoring. Individual cardiovascular genetics and androgenic sensitivity should guide duration decisions.
Mesterolone synergizes exceptionally well with all forms of exogenous testosterone. A standard protocol pairs 50mg of Mesterolone daily with 400–600mg weekly of Testosterone Enanthate or Cypionate. The Mesterolone displaces SHBG-bound testosterone, effectively increasing free hormone availability, while its weak anti-aromatase properties help manage estrogenic side effects from the testosterone base. For more aggressive aromatizing cycles involving Nandrolone or high-dose testosterone, increasing Mesterolone to 75–100mg daily or adding a dedicated aromatase inhibitor may be prudent.
No. Unlike nearly all other oral anabolic agents—including Dianabol, Anavar, and Winstrol—Mesterolone is not C17-alpha alkylated. This absence of hepatotoxic structural modification means it does not elevate hepatic transaminases, does not cause cholestatic stress, and does not require liver support supplements such as TUDCA or NAC. Standard hepatic metabolism via oxidation and glucuronidation handles the compound cleanly, making it uniquely suitable for users with existing liver concerns or those who wish to avoid the organ stress inherent to traditional oral steroids.
Mesterolone can contribute to gynecomastia management through its weak aromatase inhibition and direct androgen receptor antagonism in breast tissue, but it is generally insufficient as a standalone treatment for established gynecomastia. For early-stage, soft tissue development, combining 50mg Mesterolone daily with 20mg Tamoxifen Citrate may effectively reverse the condition. However, for fibrous, long-standing gynecomastia, more aggressive pharmaceutical or surgical intervention is typically required. Mesterolone is best viewed as a preventative adjunct rather than a curative monotherapy.
